<unk>  is a monoclonal antibody that is FDA approved for the {{{indicationType}}} of moderate to severe plaque psoriasis (Ps), active psoriatic arthritis (PsA).   Common adverse reactions include nasopharyngitis, upper respiratory tract infection, headache, and fatigue.
Ustekinumab
Nebacumab
Evolocumab
Alirocumab
Durvalumab
Lanadelumab
Dupilumab
Guselkumab